Optimizing mycophenolic acid exposure for reduced relapse risk in paediatric nephrotic syndrome: An observational cohort study
Maintaining MPA AUC<sub>0-12h</sub> ≥ 31.51 μg/h/mL significantly reduces relapse risk in paediatric NS. Individualized mycophenolate mofetil (MMF) dosing guided by therapeutic drug monitoring is critical for optimizing outcomes.
Authors
- Xiaoyun Jiang (ORCID: https://orcid.org/0000-0003-4044-2500)
- Yonghua Cai (ORCID: https://orcid.org/0000-0001-8216-9843)
- Baojing Liu
- Lu Zhang (ORCID: https://orcid.org/0000-0002-2794-7371)
- Lizhi Chen (ORCID: https://orcid.org/0000-0002-6182-5888)
- Pan Chen (ORCID: https://orcid.org/0000-0002-9324-5490)
- Kejing Tang (ORCID: https://orcid.org/0000-0002-5454-4666)
Institutions
- Sun Yat-sen University (CN)
- Zhuhai People's Hospital (CN)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
- Weihai Maternal and Child Health Hospital (CN)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2025-10-08
- DOI
- https://doi.org/10.1002/bcp.70307
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 0.00